Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Corporate Update (May 2026)
13 slides from Neurizon Therapeutics's corporate update, May 28, 2026
Slide 1: Webinar presentation - Regimen I expands to 240 participants
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Webinar presentation - Regimen I expands to 240 participants 28 May 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated
Slide 2: HEALEY ALS Platform Trial Regimen I Sample Size Expansion
For personal use only HEALEY ALS Platform Trial Regimen I Sample Size Expansion MAY 2026 ABN 35 094 006 023
Slide 3: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation Future Matters has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 4: Agenda
For personal use only Agenda • Key takeaways • Recruitment momentum and execution update • HEALEY platform dynamics and rationale for expansion • Regimen I Timeline • Financial considerations • Future milestones • Q&A Regimen I Sample Size Expansion 3
Slide 5: Key Takeaways
Key Takeaways For personal use only Neurizon announced an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements. Increase in Neurizon’s Regimen I sample size driven by the enrolment
Slide 6: Strong Phase 2/3 ALS Trial Recruitment Momentum
Strong Phase 2/3 ALS Trial Recruitment Momentum For personal use only 64 113 Regimen Assignment Activated Sites 193 74 Master Screening Dosed Participants Numbers referred to above are as of 22 May 2026. Regimen I Sample Size Expansion 5
Slide 7: Expansion of Regimen I sample from 160 to 240 participants
Expansion of Regimen I sample from 160 to 240 participants For personal use only Expansion Driven by: • Enrolment rates exceeding original expectations • Rapid U.S. site activation and strong operational execution across the Sean M. Healey & AMG Center for ALS network • Absence of a start of a concu
Slide 8: Why Expansion to 240 Matters
Why Expansion to 240 Matters? For personal use only Stronger Dataset Improved Regulatory Credibility Improves Commercial Positioning • Stronger Evidence: Generates a • Maintains statistical power aligned • Clinically meaningful benefit with larger, more informative dataset to with the original assum
Slide 9: Regimen-I Trial execution timelines exceed previous projections
‘Regimen-I’ Trial execution timelines exceed previous projections For personal use only Expanded cohort to 240 participants Based on current enrolment rate, Neurizon anticipates accelerated trial timeline projection NOW NOW NOW NOW Q3 2026 Q2 2027 Q2 2027 EARLY Q3 2027 Q4 2025 Q4 2025 Q1 2026 Q1 202
Slide 10: Financial Considerations
Financial Considerations Accelerated time to topline readout with no change in funding For personal use only requirements Cost Management & Philanthropic Contribution R&D Tax Incentive Accelerated Trial Timeline from HEALEY Additional cost being materially offset by Focused cost management and fast
Slide 11: Key Progress and Upcoming Milestones
Key Progress and Upcoming Milestones For personal use only Key Progress in Q2 Upcoming Milestones in Q2 Upcoming Milestones Q3/Q4 • Preclinical updates • HEALEY enrollment updates • CEO Appointment • VIC and QLD shareholder briefing events Ethics Approval for PMDA Regulatory Preclinical • HEALEY tab
Slide 12: Thank You
For personal use only Thank You
Slide 13: Live Q&A
For personal use only Live Q&A